Cameroon launches pilot program for long-acting injectable HIV prevention drug
Cameroon has officially launched a pilot program for Cabotegravir, a long-acting injectable drug aimed at HIV prevention. The initiative, announced by Public Health Minister Manaouda Malachie, took place in Douala and represents a significant advancement in public health strategy in the country.
Launch of the Pilot Program
The pilot program for Cabotegravir, also known as CAB-PrEP, was launched on Thursday in Douala, the economic capital of Cameroon. This initiative is part of the country's broader strategy to combat HIV and improve public health outcomes. Public Health Minister Manaouda Malachie emphasized the importance of this new preventive option during the launch event.
The introduction of CAB-PrEP marks a strategic shift in Cameroon’s approach to HIV prevention. This long-acting injectable drug is designed to provide an alternative to daily oral PrEP, potentially increasing adherence among at-risk populations. The pilot phase aims to assess the drug's effectiveness and feasibility in the local context.
Significance for Public Health
The launch of CAB-PrEP is seen as a crucial step in addressing the HIV epidemic in Cameroon, where the disease remains a significant public health challenge. By providing a long-acting injectable option, health officials hope to reduce new infections and improve the quality of life for those at risk. The program is expected to target high-risk groups, including key populations.
Minister Manaouda Malachie highlighted that the initiative aligns with global efforts to end the HIV epidemic by 2030. The government aims to gather data from this pilot program to inform future health policies and expand access to innovative prevention methods across the country.
Couverture par les sources (0)
Découvrir plus
Cameroun présente les résultats de l'enquête nationale sur le VIH CAMPHIA 2024-2025
L'enquête nationale CAMPHIA 2024-2025 a révélé un taux de réponse de 76,2 % parmi 25 083 adultes, avec 21 000 nouveaux cas de VIH recensés en 2025. Ces résultats visent à évaluer l'impact des efforts de lutte contre le VIH au Cameroun. Les données proviennent d'un échantillon de 29 029 personnes éligibles pour le dépistage.
Cameroon Faces Significant HIV Burden with 510,000 Affected Individuals
Cameroon ranks 16th globally in HIV burden, with approximately 510,000 people living with the virus. The prevalence is particularly high in urban areas like Yaoundé and Douala. A national awareness campaign aims to reach 9 million people by 2026 to combat this public health crisis.
Cameroon Launches Pandemic Fund to Enhance Health Security
On Wednesday, Cameroon officially launched the Pandemic Fund, a multi-sector financing mechanism aimed at improving the country's capacity to prevent and respond to health emergencies. The initiative includes a significant investment of $23.5 million to bolster the nation's preparedness for future pandemics. The event was presided over by the Minister of Public Health, who emphasized the importance of this funding for national health security.
Lancement d'une campagne de prévention du paludisme pour 1,5 million d'enfants dans l'Extrême-Nord
La 11ᵉ campagne de Chimio-prévention du Paludisme Saisonnier (CPS) a été lancée le 12 juin 2026 dans la région de l'Extrême-Nord du Cameroun, visant à protéger plus de 1,5 million d'enfants. Cette initiative intervient alors que les autorités sanitaires s'inquiètent des près de 3 millions de cas de paludisme enregistrés en 2025, soulignant la nécessité d'une action collective contre cette maladie.